<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002715</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064551</org_study_id>
    <secondary_id>SUMC-G2/G3</secondary_id>
    <secondary_id>NCI-H96-0806</secondary_id>
    <nct_id>NCT00002715</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma</brief_title>
  <official_title>A PHASE II PILOT STUDY OF SHORT TERM (12 WEEK) COMBINATION CHEMOTHERAPY (STANFORD V) IN UNFAVORABLE HODGKIN'S DISEASE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
      patients who have advanced Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility of short term chemotherapy with the Stanford V regimen
           (mechlorethamine, doxorubicin, vinblastine, prednisone, vincristine, bleomycin, and
           etoposide) followed by, as indicated, consolidative radiotherapy in patients with stage
           IIB, IIIA, IIIB, or IV Hodgkin's lymphoma.

        -  Determine the initial response to 8 weeks of Stanford V chemotherapy in these patients.

        -  Assess the complete and partial response rate to 12 weeks of Stanford V chemotherapy in
           these patients.

        -  Determine the acute toxicity associated with this treatment.

        -  Determine the disease free interval and survival following Stanford V chemotherapy with
           or without consolidative radiotherapy in these patients.

      OUTLINE: All patients are treated on Regimen A with the Stanford V Regimen; those with
      initial bulky, residual, or splenic disease who achieve a CR/PR proceed to Regimen B.

        -  Regimen A: Patients receive mechlorethamine IV on weeks 1, 5, and 9; doxorubicin and
           vinblastine IV on weeks 1, 3, 5, 7, 9, and 11; vincristine and bleomycin IV on weeks 2,
           4, 6, 8, 10, and 12; etoposide IV over 30-45 minutes for 2 consecutive days on weeks 3,
           7, and 11; and prednisone orally every other day on days 1-84. Treatment continues for
           8-12 weeks, depending on response, in the absence of disease progression or unacceptable
           toxicity.

        -  Regimen B: Patients begin radiotherapy 2-4 weeks after completion of Regimen A. Patients
           receive radiotherapy to lungs, pleura, and other extralymphatic sites for approximately
           5 weeks.

      Patients are followed for survival.

      PROJECTED ACCRUAL: A total of 50 patients will be entered if at least 16 of the first 22
      patients respond. As of 03/96, it is expected that a total of 45 patients each with stage
      III/IV disease and 40 with unfavorable stage II disease will be accrued.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 1989</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stanford V regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mechlorethamine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed Hodgkin's lymphoma of any histology

          -  Unfavorable disease required

               -  Clinical stage IIIA, IIIB, IV, or IIB (non-bulky)

               -  Locally extensive stage I or II with either of the following:

                    -  Mediastinal mass greater than 1/3 the maximum intrathoracic diameter

                    -  Two or more extranodal sites

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 60

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No prior malignancy except nonmelanomatous skin cancer

          -  No significant concurrent illness that precludes protocol participation

        PRIOR CONCURRENT THERAPY:

          -  No prior treatment for Hodgkin's lymphoma

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra J. Horning, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center at Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol. 1996;7 Suppl 4:105-8. Review.</citation>
    <PMID>8836420</PMID>
  </results_reference>
  <results_reference>
    <citation>Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995 May;13(5):1080-8.</citation>
    <PMID>7537796</PMID>
  </results_reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2009</last_update_submitted>
  <last_update_submitted_qc>July 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2009</last_update_posted>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
  <keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
  <keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
  <keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

